Larazotide Acetate vs Cartalax
Side-by-side comparison of key properties, dosing, and research.
Recovery & Repair
Larazotide AcetateAnti-Aging & Longevity
Cartalax- Summary
- Larazotide acetate is an 8-amino acid peptide (Gly-Gly-Val-Leu-Val-Gln-Pro-Gly) derived from Zonula Occludens Toxin (ZOT) of Vibrio cholerae. It paradoxically acts as a ZOT antagonist to close tight junctions and reduce intestinal permeability ('leaky gut'). It is the most advanced clinical compound targeting gut permeability directly.
- Cartalax is a tetrapeptide bioregulator (Ala-Glu-Asp-Pro) developed by Professor Vladimir Khavinson for cartilage and connective tissue. It is tissue-specific for chondrocytes and cartilaginous structures, supporting cartilage matrix synthesis, slowing degenerative changes, and promoting joint longevity. It is used in the context of osteoarthritis, joint aging, and athletic cartilage preservation.
- Half-Life
- Local gut action; minimal systemic exposure
- Short (minutes); gene-regulatory effects are sustained
- Admin Route
- Oral
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 0.5-2 mg
- 10 mg per day
- Frequency
- 3x daily
- Daily for 10–30 days
- Key Benefits
- Directly reduces intestinal tight junction permeability
- Clinical efficacy in celiac disease (Phase 3 trials)
- Reduces systemic inflammation from gut permeability
- Targets root cause of leaky gut (Zonulin pathway)
- Local gut action without systemic absorption
- Potential application in IBS, IBD, autoimmune conditions
- Supports cartilage matrix synthesis and maintenance
- May slow progression of osteoarthritic cartilage degradation
- Reduces chondrocyte apoptosis
- Promotes joint longevity in aging and high-impact sports
- Anti-aging effects on connective tissue
- Complementary to BPC-157 and TB-500 in joint recovery protocols
- Well tolerated in available human and animal research
- Side Effects
- Headache (mild, dose-dependent)
- Nausea (rare)
- Well-tolerated overall in clinical trials
- Generally well tolerated
- Mild injection site reactions
- No significant adverse events reported at standard doses
- Stacks With
- —
- —